Heart Attack :: Geron Demonstrates hESC-derived cardiomyocytes improve heart function after myocardial infarction
Geron Corporation (Nasdaq: GERN) today reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction.